Tolebrutinib
A medication under investigation for multiple sclerosis and other autoimmune diseases
| Tolebrutinib | |
|---|---|
| [[File:|frameless|220px|alt=|]] | |
| INN | |
| Drug class | |
| Routes of administration | Oral |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | Investigational |
| CAS Number | 1971929-97-7 |
| PubChem | 129073382 |
| DrugBank | |
| ChemSpider | 68012192 |
| KEGG | D11792 |
Overview[edit | edit source]
Tolebrutinib is an investigational Bruton tyrosine kinase (BTK) inhibitor being developed for the treatment of multiple sclerosis (MS) and other autoimmune diseases. It is designed to modulate the immune system by inhibiting the activity of BTK, a key enzyme involved in the signaling pathways of B cells and myeloid cells.
Mechanism of Action[edit | edit source]
Tolebrutinib works by selectively inhibiting BTK, which plays a crucial role in the activation and function of B cells and other immune cells. By blocking BTK, tolebrutinib aims to reduce the abnormal immune response that characterizes autoimmune diseases such as multiple sclerosis. This inhibition can potentially decrease the inflammation and damage to the nervous system seen in MS.
Clinical Development[edit | edit source]
Tolebrutinib is currently undergoing clinical trials to evaluate its safety and efficacy in patients with multiple sclerosis. These trials are designed to assess the drug's ability to reduce the frequency of relapses and slow the progression of disability in MS patients. The drug is administered orally, which may offer a convenient alternative to injectable therapies currently available for MS.
Potential Indications[edit | edit source]
While the primary focus of tolebrutinib's development is for the treatment of multiple sclerosis, its mechanism of action suggests potential applications in other autoimmune diseases. The inhibition of BTK could be beneficial in conditions where B cells and myeloid cells play a significant role in disease pathology.
Safety and Tolerability[edit | edit source]
The safety profile of tolebrutinib is being closely monitored in clinical trials. As with any investigational drug, potential side effects and adverse reactions are being evaluated to ensure the drug's safety for future use in patients.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
